Locations:
SearchAdvertisement
Discussing research into improving CAR T-cell therapy efficacy
Highly personalized treatment shrinks tumors resistant to immunotherapy
Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment
Findings from large database important to inform clinical practice
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Higher type 2 immunity observed in persistent CAR T cells
Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel
Investigational chimeric antigen receptor natural killer cell therapy NKX101 associated with promising early response in patients with relapsed/refractory acute myeloid leukemia
Driving advances in cancer care
Dedicated investigators and clinicians bring expertise in drug development and flexible study design
Tumor-infiltrating lymphocytes and natural killer cells
Advertisement
Advertisement